Alkalinization
Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Hydroxychloroquine  COVID-19 treatment studies for HCQ  C19 studies: HCQ  HCQ   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Hospitalization 95% Improvement Relative Risk Severity 27% Case -5% c19hcq.org Agarwal et al. HCQ for COVID-19 PrEP Is pre-exposure prophylaxis with HCQ beneficial for COVID-19? Prospective study of 484 patients in India Lower progression with HCQ (not stat. sig., p=0.21) Agarwal et al., medRxiv, doi:10.1101/2021.09.13.21262971 Favors HCQ Favors control
Low dose hydroxychloroquine prophylaxis for COVID-19 - a prospective study
Agarwal et al., medRxiv, doi:10.1101/2021.09.13.21262971 (Preprint)
Agarwal et al., Low dose hydroxychloroquine prophylaxis for COVID-19 - a prospective study, medRxiv, doi:10.1101/2021.09.13.21262971 (Preprint)
Sep 2021   Source   PDF  
  Twitter
  Facebook
Share
  All Studies   Meta
Small prophylaxis trial with 29 low dose HCQ and 455 control healthcare workers in India, showing no statistically significant differences.
risk of hospitalization, 94.8% lower, RR 0.05, p = 0.61, treatment 0 of 29 (0.0%), control 17 of 455 (3.7%), NNT 27, relative risk is not 0 because of continuity correction due to zero events (with reciprocal of the contrasting arm).
relative severity, 26.9% better, RR 0.73, p = 0.21, treatment 29, control 455.
risk of case, 4.6% higher, RR 1.05, p = 0.81, treatment 6 of 29 (20.7%), control 90 of 455 (19.8%).
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Agarwal et al., 14 Sep 2021, prospective, India, preprint, 1 author.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperHCQAll
Abstract: medRxiv preprint doi: https://doi.org/10.1101/2021.09.13.21262971; this version posted September 14, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission. Title: Low dose hydroxychloroquine prophylaxis for COVID-19 – a prospective study Short title: Hydroxychloroquine prophylaxis in COVID-19 Authors: RE-HCP2 COVID study group. Mayank Agarwal1, Rajat Ranka1, Prasan Kumar Panda1, Ajay Kumar2, Gaurav Chikara3, Suresh K Sharma4, Rizu Negi4, Ramanuj Samanta5, Rohit Walia6, Yogesh Arvind Bahurupi7, Sarama Saha8, Minakshi Dhar1, Prakhar Sharma9, Arvind Kumar Gupta10, UB Mishra11, Manoj Kumar Gupta12, Ravi Kant13 Affiliations: 1 Department of Internal Medicine, 2Anesthesia and Critical Care, 3Pharmacology, 4Nursing, 5 Opthalmology, 6Cardiology, 7Community and Family Medicine, 8Biochemistry, 9Pulmonary Medicine, 10 Pathology, 11 Hospital Affair, 12 Dean, 13 Director, All India Institute of Medical Sciences (AIIMS), Rishikesh, India Emails: m.agarwal95@gmail.com, ranka.rajat95@gmail.com, ajay.anaes@aiimsrishikesh.edu.in, motherprasanna@rediffmail.com, chikaraicon.gaurav@gmail.com, suresh.nur@aiimsrishikesh.edu.in, ramanuj.samanta@gmail.com, rohit.cardio@aiimsrishikesh.edu.in, dr.yogeshab@gmail.com, sarama.bchem@aiimsrishikesh.edu.in, minakshi.dhar@rediffmail.com, drprakhar2009@gmail.com, arvindgupta.path@gmail.com, ubsugandha@hotmail.com, manoj.rt@aiimsrishikesh.edu.in, ravibina@gmail.com, Correspondence: Prasan Kumar Panda Associate Professor, Dept. of Medicine (Infectious disease division), Sixth Floor, College Block, All India Institute of Medical Sciences (AIIMS), Rishikesh, India, 249203 Mob: +91-9868999488 Email: motherprasanna@rediffmail.com NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice. medRxiv preprint doi: https://doi.org/10.1101/2021.09.13.21262971; this version posted September 14, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission. Abstract Background: Since the outbreak of COVID-19 pandemic, the world began a frantic search for possible prophylactic options. While trials on hydroxychloroquine (HCQ) prophylaxis are ongoing, concrete evidence is lacking. The study aimed to determine the relative efficacy of various doses of oral HCQ in prophylaxis and mitigating the severity of COVID-19 in healthcare workers. Methods: This was a prospective cohort with four arms (high, medium, low dose, and control) of HCQ prophylaxis, used by healthcare workers at a tertiary care center in India. Participants were grouped as per their opting for any one arm on a voluntary basis as per institute policy under the Government guidance. The outcomes studied were COVID-19 positivity by RT-PCR and its severity assessed by WHO COVID-19 severity scale. Results: Total 486 participants were enrolled, of which 29 (6%) opted for low dose, 2 (<1%) medium dose, and none for high dose HCQ while 455 (93.6%) were in the control arm. Of the 164 participants who underwent RT-PCR, 96 (58.2%) tested positive. Out of these 96 positive cases, the majority of them (79 of 96 [82.3%]) were ambulatory and..
Loading..
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit